COMPANY FACTS

This year, Cromos Pharma proudly marks its 20th anniversary, celebrating two decades of dedication to advancing clinical research. Over the past 20 years, we have consistently delivered high-quality services, successfully navigating the complexities of clinical trials across multiple regions. Our journey has been defined by our commitment to innovation, collaboration, and the highest standards of patient care. As we look to the future, we remain focused on continuing to provide exceptional service and contributing to the development of groundbreaking therapies worldwide.

Cromos Pharma is pleased to announce a strategic partnership with Syngene International, boosting our capacity for high-quality execution and global clinical trial coverage. This alliance streamlines patient recruitment across the US, Europe, and India, while providing comprehensive clinical development services. Together, we ensure superior project management for seamless global trial execution and unified project updates, strengthening our ability to meet the demands of the evolving clinical research landscape.

Cromos Pharma achieves a significant milestone as Georgia approves its inaugural GMO clinical trial, marking a notable advancement in the country's medical research sector. This pioneering accomplishment not only underscores the company's commitment to scientific advancement but also prompts a comprehensive reflection on the intricate regulatory landscape governing GMO trials in the US and EU.

Cromos Pharma is proud to announce the successful completion of its largest EU submission to date via the Clinical Trials Information System (CTIS). Our team expertly navigated the submission process, delivering comprehensive dossiers for both Part 1 and Part 2 across 10 countries. As we continue to master this new regulatory paradigm, we are excited to assist more clients in launching their clinical trials in the EU.

Cromos Pharma enrolled three times more patients in Türkiye than in all other countries combined for its Ulcerative Colitis trial, highlighting strong local partnerships and regulatory expertise.

Cromos Pharma is strengthening its presence in Türkiye, Kazakhstan and Serbia by establishing local legal entities, opening full-scale offices, and increasing the local staff presence. 

In 2021, Cromos Pharma achieved an important milestone as it reached 10,000 patients enrolled in its oncological studies. Cromos Pharma also managed its first trial investigating a vaccine for COVID-19.

The COVID-19 pandemic dominated 2020. Cromos Pharma was proud to play its part in the fight against the virus by managing its first global clinical trial of a drug to treat severe COVID-19 infection. Throughout 2020, Cromos Pharma continued to manage successful clinical trials related to COVID-19 as well as a wide-range of other therapeutic areas.

The opening of the new office strengthened Cromos Pharma’s position in Poland where it has been operational since 2015.

With a new clinical operations base in South Florida, Cromos™ Pharma is poised to better serve US and international clients who seek FDA approval and access to North, Central and South America.

Cromos™ Pharma launched its first clinical trial in Kazakhstan, an emerging clinical trial destination in Central Asia.

By analyzing study population, sites’ motivation to enroll, type of disease, subjects’ barriers to participation in the studies, we developed a comprehensive system of recruitment optimization.

Further geographic expansion included opening a representative office in Budapest, Hungary.

Cromos™ Pharma started to provide clinical trials services in Armenia, an unsaturated area for clinical research.

Cromos™ Pharma's European presence expanded further with the starting of operations in Romania.

Successful initiation of two studies in Czech Republic led to the opening of an office in Prague.

The start of operations in Poland allowed Cromos™ Pharma to enter one of the most prominent Eastern European clinical trials markets.

Initiation of operations in Israel allow Cromos™ Pharma to expand its capabilities in running cutting-edge pharmaceutical and medical device trials.

Continuing Cromos™ Pharma's strategy for geographical expansion, operations in Bulgaria were started with an arterial hypertension trial.

Including Slovak sites into an international phase III study in NSCLC marked the beginning of Cromos™ Pharma's high grade operations in this country.

Cromos™ Pharma announced the launch of operations in Czech Republic.

Cromos™ Pharma continued to expand its geography and started operations in Belarus with a successful international multi-centre trial in patients with angina pectoris.

Cromos™ Pharma's EU Headquarters established in Dublin, Ireland, as part of the company's further growth strategy in EU market.

Cromos™ Pharma opened an office in the capital city of Tbilisi and started to provide full service support for clinical trials in Georgia.

Cromos™ Pharma initiated operations in Moldova.

After several steady years of expansion the second office in Russia in the city of Smolensk was established.

Cromos™ Pharma started operations in Estonia by successfully participating in an international multi-centre study in chronic heart failure.

Cromos™ Pharma continued to strengthen its market presence by starting activities in Lithuania.

Cromos™ Pharma started operations in Latvia with initiation of studies in dermatology.

After two years of successful growth of operations in Ukraine Cromos™ Pharma opened an office and registered a local legal entity.

Cromos™ Pharma office opened in Moscow, Russia.

Soon after beginning operations in Russia, Cromos™ Pharma added operations in Ukraine.

Cromos™ Pharma was founded in 2004 in Portland, Oregon, USA.